Altimmune, Inc. (NASDAQ:ALT) Shares Acquired by Stifel Financial Corp

Stifel Financial Corp lifted its holdings in shares of Altimmune, Inc. (NASDAQ:ALT) by 77.4% in the third quarter, HoldingsChannel reports. The firm owned 17,752 shares of the company’s stock after acquiring an additional 7,746 shares during the period. Stifel Financial Corp’s holdings in Altimmune were worth $109,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Creative Planning increased its position in Altimmune by 20.5% during the third quarter. Creative Planning now owns 18,411 shares of the company’s stock worth $113,000 after buying an additional 3,132 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Altimmune by 2.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock valued at $1,299,000 after acquiring an additional 4,772 shares during the last quarter. Larson Financial Group LLC purchased a new stake in Altimmune during the 3rd quarter worth about $31,000. Arizona State Retirement System raised its stake in Altimmune by 34.4% in the 2nd quarter. Arizona State Retirement System now owns 19,847 shares of the company’s stock valued at $132,000 after purchasing an additional 5,081 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in Altimmune by 30.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,973 shares of the company’s stock valued at $179,000 after purchasing an additional 6,339 shares in the last quarter. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. UBS Group assumed coverage on shares of Altimmune in a report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Altimmune in a research note on Thursday, November 14th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $20.00.

Altimmune Stock Performance

Altimmune stock opened at $7.32 on Tuesday. The company has a market cap of $520.64 million, a price-to-earnings ratio of -4.72 and a beta of 0.15. Altimmune, Inc. has a 1 year low of $5.28 and a 1 year high of $14.84. The firm has a 50 day moving average price of $8.02 and a 200 day moving average price of $7.14.

Altimmune (NASDAQ:ALT) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The business had revenue of $0.01 million during the quarter. During the same quarter in the previous year, the company earned ($0.39) earnings per share. Sell-side analysts predict that Altimmune, Inc. will post -1.36 EPS for the current year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.